Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the sale, the chief executive officer now owns 520,661 shares of the company’s stock, valued at $9,080,327.84. This represents a 9.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.80, for a total value of $350,839.00.

Centessa Pharmaceuticals Stock Down 2.2 %

NASDAQ:CNTA traded down $0.39 during mid-day trading on Friday, reaching $17.16. The stock had a trading volume of 791,268 shares, compared to its average volume of 434,271. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -11.22 and a beta of 1.52. Centessa Pharmaceuticals plc has a 1-year low of $6.65 and a 1-year high of $18.97. The stock’s 50 day simple moving average is $16.64 and its two-hundred day simple moving average is $13.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on CNTA. Guggenheim boosted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Jefferies Financial Group raised their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.83.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. HighMark Wealth Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $840,000. TD Asset Management Inc grew its holdings in shares of Centessa Pharmaceuticals by 40.5% during the second quarter. TD Asset Management Inc now owns 321,168 shares of the company’s stock valued at $2,900,000 after purchasing an additional 92,524 shares during the last quarter. American Century Companies Inc. raised its position in shares of Centessa Pharmaceuticals by 1.3% during the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock worth $8,444,000 after purchasing an additional 12,031 shares during the period. XTX Topco Ltd bought a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter worth approximately $148,000. Finally, Farallon Capital Management LLC boosted its position in Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 1,625,000 shares during the period. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.